. The company’s pipeline contains 4 clinical-stage therapies. Its most Highly developed drug candidate is ROS1 inhibitor taletrectinib for treating lung cancer. Nuvation is completing two section 2 pivotal experiments on taletrectinib.Most data tables is often analyzed using "Views." A Check out merely offers the symbols to the webpage with a dif